June 08, 2021
Article
The approval for Biogen’s disease-modifying, anti-amyloid agent aducanumab follows a long regulatory journey.
March 19, 2021
At the 76-week mark, reductions in the amyloid plaque level were 85.06 centiloids with donanemab than with placebo.
February 05, 2021
The Cassava Sciences agent showed 6-month improvements in both ADAS-Cog and NPI scores, and a phase 3 trial is expected to begin in late 2021.
December 08, 2020
After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.
Carla Lamb, MD: Innovations in CT Scan Accuracy
Tapinarof Cream Benefits Psoriasis Regardless of Baseline Disease Severity, Duration
Philip Mease, MD: Guselkumab Addresses the Complexities of Treating Psoriatic Arthritis